## RECEIVEDIO. 1335 P. 7 CENTRAL FAX CENTER

AUG 1 8 2005

VIA FAX TO: (571) 273-8300 (In Duplicate)

PTO/SB/25 (09-04)

Approved for use dirough 67/31/2008. Ohl9 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a well Ohl9 control number.

ERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL POLIDIE BAYERS

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING Docket Number (Optional) REJECTION OVER A PENDING "REFERENCE" APPLICATION 02-027 CIP in re-Application of ERIC J BECKMAN et. al. Application No.: 10/789,900 Filed: FEBRUARY 27, 2004 FOR SYNTHESIS OF N-VINYL FORMAMIDE UNIVERSITY OF PITTEBURGH The owner. UNIVERSITY OF PITTSBURGH, of 60 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the copiration date of the full statutory term of any patent granted on pending reference Application Number 10/652,104 filed on AUGUST 29,2003, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the instant application and is percent interest in the instant application hereby disclaims. binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference entain to the expression care or the statutory term as teamers in 30 to 30.5. The title try or any patient granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patient on the pending reference application, in the event that; any such patient; granted on the pending reference application, and the pending reference application application of the pending reference application, and the pending reference application application of the pending reference application, and the pending reference application application are the pending reference application. The pending reference application are the pending reference application and the pending reference application are the pending reference application. terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below, if appropriate. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency. etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made havein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisoranent, or both, under Section 1001 of Title 18 of the United States Code and that such withit false statements may jeopardize the validity of the application or any patent issued thereon. 2. The undersigned is an attorney or agent of record. Reg. No. 34.772 Henry E. Bartomy ( August 18, 2005 HENRY E. BARTONY, JR. (412) 338-8632 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) is included. The Commissioner for Patents is hereby authorized to charge the tee under Section 1.20(d) to USFTO Deposit Account 02-1065. A duplicate copy of this Terminal Disclaimer is provided herewith. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. \*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324. This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiating is governed by 35 U.S.C. 122 and 37 CFR 1.141 and 1.14. This collection is estimated to both 12 minutes to complete, including patheting, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be early to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PAGE 7/9 \* RCVD AT 8/18/2005 8:39:30 AM (Eastern Dayligh) Time) \* SVR:USPTO-EFXRF-6/26 \* DNIS:2738300 \* CSID:14123386611 \* DURATION (Indu-ss):02-48

2814-65